Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Medical Officer | August 28, 2026 | September 01, 2026 |
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,776 |
Ending reported balance
After 2026-08-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 679 · Balance 52,455 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Row 2 · 2026-08-28 · Sale · Disposed 679 · Balance 51,776 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 · Expires 2035-01-28 | Direct | 113,734 |
Reported balance
After 2026-08-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-28 · Exercise / conversion · Disposed 679 · Balance 113,734 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
F2: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Cullinan Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2026-06-16 | Direct | 21,781 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 21,781 · Balance 21,781 F1: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DICE Therapeutics, Inc.
Report date August 09, 2023 · Filed August 09, 2023
Section 16 reporting ended · disclosed 2023-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2032-03-31 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-09 · Disposition to issuer · Disposed 42,500 · Balance 0 F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested.
F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant.
F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 20:38 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 679 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000031 · form4-09012026_080946.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,734 Underlying: Common Stock · 679 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:38 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 679 | $20.00 | $13,580.00 |
DisclosureSEC source: 0001918845-26-000031 · form4-09012026_080946.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:38 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 679 | $8.04 | $5,459.16 |
DisclosureSEC source: 0001918845-26-000031 · form4-09012026_080946.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000029 · form4-08192026_040810.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 1,000 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 1,000 | $20.00 | $20,000.00 |
DisclosureSEC source: 0001918845-26-000029 · form4-08192026_040810.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 1,000 | $12.65 | $12,650.00 |
DisclosureSEC source: 0001918845-26-000029 · form4-08192026_040810.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 679 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000026 · form4-08122026_040801.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,413 Underlying: Common Stock · 679 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 679 | $20.00 | $13,580.00 |
DisclosureSEC source: 0001918845-26-000026 · form4-08122026_040801.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 679 | $8.04 | $5,459.16 |
DisclosureSEC source: 0001918845-26-000026 · form4-08122026_040801.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000024 · form4-07292026_040701.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,750 Underlying: Common Stock · 1,000 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 1,000 | $20.00 | $20,000.00 |
DisclosureSEC source: 0001918845-26-000024 · form4-07292026_040701.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 1,000 | $12.65 | $12,650.00 |
DisclosureSEC source: 0001918845-26-000024 · form4-07292026_040701.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,779 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000022 · form4-07022026_040722.xml · derivative · entry 5 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,092 Underlying: Common Stock · 1,779 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F3 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000022 · form4-07022026_040722.xml · derivative · entry 4 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,750 Underlying: Common Stock · 2,875 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 4,654 | $20.00 | $93,080.00 |
DisclosureSEC source: 0001918845-26-000022 · form4-07022026_040722.xml · nonDerivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 1,779 | $8.04 | $14,303.16 |
DisclosureSEC source: 0001918845-26-000022 · form4-07022026_040722.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 2,875 | $12.65 | $36,368.75 |
DisclosureSEC source: 0001918845-26-000022 · form4-07022026_040722.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,450 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000020 · form4-06252026_090648.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,871 Underlying: Common Stock · 1,450 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 1,450 | $18.00 | $26,100.00 |
DisclosureSEC source: 0001918845-26-000020 · form4-06252026_090648.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 1,450 | $8.04 | $11,658.00 |
DisclosureSEC source: 0001918845-26-000020 · form4-06252026_090648.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 21,781 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276054 · ownership.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,781 Underlying: Common Stock · 21,781 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:26 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 1,084 | $13.10 | $14,200.40 |
DisclosureSEC source: 0001918845-26-000018 · form4-06122026_080645.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,776 F1 · balance_after: Includes 5,738 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 679 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000016 · form4-06012026_040618.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,321 Underlying: Common Stock · 679 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 679 | $16.00 | $10,864.00 |
DisclosureSEC source: 0001918845-26-000016 · form4-06012026_040618.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,122 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 679 | $8.04 | $5,459.16 |
DisclosureSEC source: 0001918845-26-000016 · form4-06012026_040618.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantCommon Stock | 43,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001918845-26-000014 · form4-05262026_040503.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,122 F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000012 · form4-05192026_040503.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,625 Underlying: Common Stock · 3,000 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 3,000 | $18.76 | $56,280.00 |
DisclosureSEC source: 0001918845-26-000012 · form4-05192026_040503.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 3,000 | $12.65 | $37,950.00 |
DisclosureSEC source: 0001918845-26-000012 · form4-05192026_040503.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 14 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 28,650 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 77,905 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 13 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,625 Underlying: Common Stock · 77,905 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F6 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 10,058 | $22.88 | $230,127.04 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 10 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 19,015 | $22.41 | $426,050.09 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 9 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,680 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F5 · price: The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 44,944 | $21.20 | $952,668.98 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 8 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,695 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 5,000 | $19.65 | $98,251.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 7 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,639 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 27,538 | $18.03 | $496,405.50 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 6 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,639 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 28,650 | $8.04 | $230,346.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 5 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 77,905 | $12.65 | $985,498.25 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 4 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 679 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 12 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,650 Underlying: Common Stock · 679 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 11 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,530 Underlying: Common Stock · 1,000 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F6 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 1,679 | $16.00 | $26,864.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 679 | $8.04 | $5,459.16 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 1,000 | $12.65 | $12,650.00 |
DisclosureSEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,970 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001918845-26-000008 · form4-04082026_080437.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,530 Underlying: Common Stock · 3,970 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F3 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 3,970 | $18.01 | $71,508.43 |
DisclosureSEC source: 0001918845-26-000008 · form4-04082026_080437.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 3,970 | $12.65 | $50,220.50 |
DisclosureSEC source: 0001918845-26-000008 · form4-04082026_080437.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 679 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000006 · form4-04032026_070418.xml · derivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,329 Underlying: Common Stock · 679 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 679 | $16.00 | $10,864.00 |
DisclosureSEC source: 0001918845-26-000006 · form4-04032026_070418.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:13 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 679 | $8.04 | $5,459.16 |
DisclosureSEC source: 0001918845-26-000006 · form4-04032026_070418.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:07 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,992 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001918845-26-000004 · form4-03182026_080310.xml · derivative · entry 5 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,008 Underlying: Common Stock · 5,992 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.